+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Esophageal Cancer Market by End User, Cancer Type, Disease Stage, Treatment Type - Global Forecast to 2030- Product Image
Esophageal Cancer Market by End User, Cancer Type, Disease Stage, Treatment Type - Global Forecast to 2030- Product Image
Sale

Esophageal Cancer Market by End User, Cancer Type, Disease Stage, Treatment Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967803
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The esophageal cancer market, shaped by aggressive disease dynamics and rapid advances in detection and therapy, faces rising complexity as clinical, technological, and regulatory forces intersect. Senior decision-makers require targeted insights to navigate shifting innovation, cost pressures, and global healthcare trends while identifying sustainable growth opportunities.

Market Snapshot: Esophageal Cancer Market Overview

The Esophageal Cancer Market expanded from USD 16.08 billion in 2024 to USD 17.45 billion in 2025 and is projected to grow at a CAGR of 8.33%, reaching USD 26.01 billion by 2030. Increased disease incidence, a surge in immunotherapy adoption, and evolving regulatory frameworks are collectively fueling market momentum across regions and segments. Advances in endoscopic screening and early-stage therapies are creating new opportunities and competitive stakes for industry leaders.

Scope & Segmentation: Esophageal Cancer Market Coverage

This report delivers comprehensive, actionable analysis for the global esophageal cancer market, offering critical segment breakdowns to guide strategic decisions. Segments examined include:

  • End User: Ambulatory surgical centers, hospitals, specialty clinics.
  • Cancer Type: Adenocarcinoma, squamous cell carcinoma.
  • Disease Stage: Stage I, Stage II, Stage III, Stage IV.
  • Treatment Type: Chemotherapy (adjuvant, neoadjuvant, palliative), immunotherapy (cancer vaccines, checkpoint inhibitors), radiotherapy, surgery, targeted therapy (EGFR, HER2, VEGF inhibitors).
  • Region: Americas (including United States, Canada, Mexico, Brazil, and Argentina), Europe/Middle East/Africa (including major Western and emerging markets), and Asia-Pacific (China, India, Japan, Australia, and others).
  • Leading Companies: Merck & Co., Bristol-Myers Squibb, Roche, Johnson & Johnson, AstraZeneca, Pfizer, Novartis, Amgen, AbbVie, Sanofi.

Innovations in imaging, molecular diagnostics, and targeted therapeutics are mapped to current trends and market adoption patterns.

Key Takeaways for Decision-Makers

  • Novel immunotherapies and targeted treatments are rapidly changing the standard of care, prompting reevaluation of clinical pathways and investment priorities.
  • Earlier diagnosis, propelled by advanced endoscopic technologies and increased screening awareness, is improving patient outcomes and shaping service delivery models.
  • Strategic alliances between pharmaceutical, biotech, and device manufacturers are expediting product development and enhancing competitive positioning across crowded therapeutic landscapes.
  • Patient advocacy and value-based healthcare models demand clear evidence of both clinical efficacy and cost-effectiveness, influencing reimbursement and access strategies.
  • Segment-specific insights enable portfolio differentiation, especially in advanced-stage and molecularly defined patient cohorts requiring tailored regimens.
  • Regional investment in healthcare capacity and technology adoption varies markedly, necessitating localized approaches to market entry and resource allocation.

Tariff Impact on Market Complexity

New tariff measures introduced in 2025 are driving up costs for diagnostic imaging equipment and imported therapies, increasing supply chain pressures throughout the esophageal cancer sector. Manufacturers face higher production expenses, and providers must balance affordability with quality standards. To maintain continuity and mitigate geopolitical risk, stakeholders are exploring diverse sourcing and domestic manufacturing partnerships. Despite immediate challenges, these shifts could ultimately strengthen sector resilience and supply reliability worldwide.

Methodology & Data Sources

This report is based on an integrated, multi-source research methodology. Primary data include expert interviews with thought leaders, oncologists, and supply chain executives. Secondary sources comprise financial statements, regulatory publications, epidemiological data, and healthcare expenditure registries. Rigorous data triangulation ensures consistency, with quality control by subject matter specialists and verification against public benchmarks.

Why This Report Matters: Strategic Advantages

  • Clarifies critical trends and actionable segment opportunities in the global esophageal cancer market for risk-aware, growth-focused leaders.
  • Equips organizations to navigate complex regulatory, tariff, and reimbursement landscapes with sharper perspective on regional drivers and technology adoption.
  • Supports portfolio optimization, resource allocation, and long-term value creation in an evolving therapeutic environment.

Conclusion

This executive summary provides a structured analysis of the esophageal cancer market landscape, distilling actionable intelligence to support high-level strategy. Proactive adaptation to innovation, regulation, and competitive evolution will drive sustainable advantages for senior decision-makers and stakeholders.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of esophageal cancer and need for timely treatment
5.1.1.2. Development of sophisticated esophageal cancer diagnostic techniques
5.1.1.3. Government initiatives and funding for cancer research
5.1.2. Restraints
5.1.2.1. Adverse recalls of esophageal cancer drugs
5.1.3. Opportunities
5.1.3.1. Advancements in esophageal cancer medications with favorable government approvals
5.1.3.2. Emergence of targeted therapies and immunotherapies
5.1.4. Challenges
5.1.4.1. Complexity in development of therapeutics
5.2. Market Segmentation Analysis
5.2.1. Type: High prevalence of esophageal squamous-cell carcinoma owing to smoking, alcohol consumption, other toxic habits
5.2.2. Treatment: Adoption of chemotherapy and radiotherapy in combination before surgery
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Esophageal Cancer Market, by Type
6.1. Introduction
6.2. Esophageal Adenocarcinoma
6.3. Esophageal Squamous-Cell Carcinoma
7. Esophageal Cancer Market, by Cancer Phase
7.1. Introduction
7.2. Phase I
7.3. Phases II
7.4. Phases III
8. Esophageal Cancer Market, by Treatment
8.1. Introduction
8.2. Chemotherapy
8.3. Radiotherapy
8.4. Surgery
9. Esophageal Cancer Market, by End-Users
9.1. Introduction
9.2. Cancer Research Institutes
9.3. Diagnostic Laboratories
9.4. Hospitals & Clinics
10. Americas Esophageal Cancer Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Esophageal Cancer Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Esophageal Cancer Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Sugemalimab Plus Chemo Receives Approval in China for Esophageal Squamous Cell Carcinoma
13.3.2. China-based biotech receives approval for esophageal cancer treatment
13.3.3. Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ESOPHAGEAL CANCER MARKET RESEARCH PROCESS
FIGURE 2. ESOPHAGEAL CANCER MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ESOPHAGEAL CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ESOPHAGEAL CANCER MARKET DYNAMICS
TABLE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL ADENOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL SQUAMOUS-CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES II, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES III, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 35. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 37. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 39. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 57. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 59. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 60. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 61. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 63. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 64. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 69. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 71. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 72. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 93. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 95. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 96. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 108. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 109. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 110. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 114. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 116. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 118. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 121. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 130. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 132. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 142. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 143. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 144. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 145. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 146. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 148. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 149. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 150. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 152. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 153. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 166. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 169. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 178. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 180. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 181. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 190. ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
TABLE 191. ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Esophageal Cancer market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • Johnson & Johnson
  • AstraZeneca PLC
  • Pfizer Inc.
  • Novartis AG
  • Amgen Inc.
  • AbbVie Inc.
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 17.45 Billion
Forecasted Market Value ( USD ) by 2030 $ 26.01 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Esophageal Cancer Drugs - Global Strategic Business Report - Product Image

Esophageal Cancer Drugs - Global Strategic Business Report

  • Report
  • 269 Pages
  • Global
From
Esophageal Cancer Market Report and Forecast 2025-2034 - Product Image

Esophageal Cancer Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Esophageal Cancer Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Esophageal Cancer Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Esophageal Cancer Market Report 2025 - Product Image

Esophageal Cancer Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Esophageal Cancer Drug Pipeline Analysis Report 2025 - Product Image

Esophageal Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Esophageal Cancer Drug Market

Esophageal cancer is a type of cancer that affects the esophagus, the tube that connects the throat to the stomach. Oncology drugs are used to treat this type of cancer, and the esophageal cancer drug market is a subset of the larger oncology drug market. These drugs are used to treat both early and advanced stages of the disease, and can include chemotherapy, targeted therapy, and immunotherapy. Esophageal cancer drugs are typically administered orally or intravenously, and can be used in combination with other treatments such as radiation therapy. The market for esophageal cancer drugs is expected to grow due to the increasing prevalence of the disease, as well as advances in drug development and delivery. Some companies in the esophageal cancer drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.